4-Hydroxybutyric Acid

If a child in your family has had unexplained developmental delays, low muscle tone, seizures, or unusual behavior, this is the test that can point to a specific metabolic cause. Urinary 4-hydroxybutyric acid (also called GHB, gamma-hydroxybutyric acid) is the chemical fingerprint of a rare inherited disorder that disrupts how the brain processes one of its most important signaling chemicals.

In adults, the same test serves a very different purpose. It is the standard way to detect exposure to GHB as a drug, whether the question is intoxication, overdose, or forensic confirmation. One test, two completely different stories, depending on how high the level is and the clinical context.

What This Marker Actually Reflects

4-hydroxybutyric acid, more commonly known as GHB, is produced naturally in small amounts as part of how your brain breaks down GABA (gamma-aminobutyric acid), the main calming signal in the nervous system. A specific enzyme called SSADH (succinic semialdehyde dehydrogenase) normally finishes this breakdown. When that enzyme is missing or broken, GHB and related byproducts pile up and spill into the urine.

Because only about 1 to 2 percent of any GHB in the body shows up unchanged in urine, and the molecule clears with a half-life of roughly 0.5 to 0.9 hours, this is a fast-moving signal. Urine extends the detection window by about 3 to 4 hours compared with blood, but timing still matters more than for almost any other lab test.

SSADH Deficiency: The Inherited Disorder Behind High Levels

Persistently elevated urinary GHB is the biochemical hallmark of SSADH deficiency, also called 4-hydroxybutyric aciduria. The standard diagnostic pattern in clinical practice also includes 4,5-dihydroxyhexanoic acid, 3-hydroxypropionic acid, dicarboxylic acids, and elevated glycine. This is the disorder the test is designed to catch in clinical practice.

Across the largest case series describing 23 patients, and a 51-patient clinical spectrum study, the picture that emerges is consistent: mild to moderate developmental delay, low muscle tone in infancy, language difficulty, and in many patients, seizures. Behavior can swing in either direction, from extreme hyperactivity to deep sleepiness. Multiple adult patients have been documented in cohort studies, including one diagnosed as late as age 63, so this is not a disorder that only presents in childhood.

A 5-year natural history study of 62 people with SSADH deficiency found that symptoms can worsen with age, though communication and motor function often improve. A separate study of 103 patients linked epilepsy onset and severity to reduced brain GABA signaling, helping explain why seizures are such a common feature.

Cancer Metabolism Connection

In a study of ovarian high-grade serous cancer, tumor tissue and serum showed accumulation of hydroxybutyric acid metabolites, including 3,4-dihydroxybutyric and 2,4-dihydroxybutyric acids. Higher levels were tied to worse overall survival and to low activity of the same SSADH enzyme implicated in the inherited disorder.

This is a research finding rather than a clinical use of the test. Urinary 4-hydroxybutyric acid is not currently used to screen for or monitor cancer in healthy adults. The link matters because it shows that the same metabolic pathway that goes wrong in a rare genetic disease can also be disrupted in certain cancers.

Detecting Exogenous GHB Exposure

In adults without inherited metabolic disease, urinary GHB is normally very low. Antemortem urine series found typical concentrations well under the forensic threshold, with one large dataset reporting a narrow range across roughly 200 samples.

Forensic toxicology generally uses a urine cutoff to suggest someone took GHB from an outside source rather than producing it naturally. A later study of 100 cases proposed lowering that threshold in living people to avoid missing real exposures.

Even with the right cutoff, GHB clears quickly. In an emergency department study of 506 patients, doctors could often diagnose GHB intoxication clinically, but they tended to underestimate how often it was present without an analytical test to confirm it. A study conducted in metropolitan Adelaide, South Australia enrolled 1,120 patients presenting with drug intoxication symptoms; 309 (27.6%) tested positive for GHB, and GHB intoxication frequently led to ICU-level care.

Tracking Your Trend

For someone diagnosed with SSADH deficiency, serial measurement of urinary 4-hydroxybutyric acid can be part of metabolic follow-up. In a case report tracking response to the medication vigabatrin, monitoring 4-hydroxybutyric acid levels in body fluids was used to gauge biochemical changes during treatment. A single value is rarely enough to guide decisions on its own.

Urinary levels also vary within a single day. In a study of healthy women, GHB and most related metabolites differed significantly across four time blocks of the same day, mostly because of urine concentration and the body's daily rhythm. Across two separate days, however, levels were stable. Adjusting for creatinine, a standard urine concentration marker, removed most of the within-day swing.

If you are tracking a known disorder or response to therapy, collect samples at the same time of day, request creatinine adjustment, and look at the trend across multiple measurements rather than reacting to any single result.

When Results Can Be Misleading

A few things can distort a single urine measurement of 4-hydroxybutyric acid and lead to the wrong conclusion:

• Timing relative to GHB exposure: because GHB clears in well under an hour, a sample collected even a few hours late can read as normal in someone who actually took the drug. Urine adds roughly 3 to 4 hours over blood, but the window is still short.
• Urine concentration: dilute samples can mask real elevations and concentrated samples can falsely raise the number. Creatinine adjustment compensates for this and makes results more comparable.
• Time of day: within-day variation is significant in healthy people. Comparing a morning sample to an evening sample without correction can mimic a real change.
• Sedation with medical GHB: medical use of 4-hydroxybutyric acid as a sedative can produce intermittent elevations in urine that, if not disclosed, can be mistaken for the inherited disorder.

What to Do With an Unexpected Result

A markedly elevated urinary 4-hydroxybutyric acid in a child or adult with developmental delay, seizures, or hypotonia should prompt confirmatory workup for SSADH deficiency. This typically means quantitative organic acid analysis, evaluation of related metabolites such as 4,5-dihydroxyhexanoic acid, 3-hydroxypropionic acid, and dicarboxylic acids, enzyme activity testing in cells, and genetic testing of the ALDH5A1 gene. Involvement of a metabolic geneticist or pediatric neurologist is appropriate.

In an adult without symptoms of metabolic disease, an elevation above the forensic cutoff suggests exogenous GHB exposure. Whether intentional or unintentional, this is a context for a broader toxicology screen rather than for repeat metabolic testing. In a borderline case, related markers such as 2,4-dihydroxybutyric acid, GHB-glucuronide, or GHB-glycine can sometimes extend the interpretive window, though none has fully replaced GHB itself as the primary signal.